Tango Therapeutics, Inc. (TNGX)

NASDAQ:
TNGX
| Latest update: Mar 9, 2026, 7:46 PM

Price Chart

$16.44

2.99%
(1 month)

Top Shareholders

Farallon Capital Management LP
9.70%
EcoR1 Capital, LLC
9.55%
TCG Crossover Management LLC
9.48%
Boxer Holdings LP
8.08%
Adage Capital Partners GP LLC
7.88%
Woodline Partners Holdings LP
7.48%
BlackRock, Inc.
6.34%
The Invus Group LLC
6.06%

Sentiment for TNGX

News
Social

Buzz Talk for TNGX

Today

Social Media

General

Stock events for Tango Therapeutics, Inc. (TNGX)

Tango Therapeutics' stock price has increased significantly, with a 525.00% increase between March 4, 2025, and March 3, 2026. The stock jumped 36.3% following a clinical trial collaboration with Erasca. Tango Therapeutics reported its Q4 and full-year 2025 financial results, with $343.1 million in cash and collaboration revenue of $62.4 million. The company is on track to initiate a pivotal study for vopimetostat monotherapy in 2026. Malte Peters was appointed as the new CEO, and Sung Lee joined the Board of Directors. Mizuho initiated coverage with an outperform rating, and Stifel maintained its Buy rating. Management has been presenting at major healthcare conferences.

Demand Seasonality affecting Tango Therapeutics, Inc.’s stock price

There is no discernible demand seasonality for Tango Therapeutics, Inc.'s products and services. The demand for their investigational therapies is driven by the progression of clinical trials, regulatory approvals, and the unmet medical needs in specific cancer populations.

Overview of Tango Therapeutics, Inc.’s business

Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing precision oncology therapies. They operate in the healthcare sector, leveraging synthetic lethality to identify novel drug targets, particularly for tumor suppressor gene loss. Their major product candidates include TNG908 (Vopimetostat), TNG462, TNG260, TNG348, and TNG456, targeting various cancers.

TNGX’s Geographic footprint

Tango Therapeutics, Inc. primarily conducts its business activities in the United States, with its headquarters located in Boston, Massachusetts.

TNGX Corporate Image Assessment

Tango Therapeutics' brand reputation is largely positive due to advancements in its clinical pipeline and strategic collaborations. Positive clinical developments and strategic partnerships have generated investor interest. The company's financial stability and leadership changes have also positively impacted its reputation. TNGX has significantly outperformed the market, indicating strong investor confidence.

Ownership

Tango Therapeutics, Inc. has significant institutional ownership, with 203 institutional owners and shareholders holding 153,680,985 shares. Major owners include Farallon Capital Management Llc, Boxer Capital Management, LLC, and Ecor1 Capital LLC, which is the largest individual shareholder. Institutional shareholders hold 128.08% of the stock, insiders hold 61.80%, and retail investors hold 0.00%.

FAQ

What is the current stock price of Tango Therapeutics, Inc.?

As of the latest update, Tango Therapeutics, Inc.'s stock is trading at $16.44 per share.

What’s happening with Tango Therapeutics, Inc. stock today?

Today, Tango Therapeutics, Inc. stock is down by -2.99%, possibly due to news.

What is the market sentiment around Tango Therapeutics, Inc. stock?

Current sentiment around Tango Therapeutics, Inc. stock is positive, based on recent news, trading volume, and analyst opinions.

Is Tango Therapeutics, Inc.'s stock price growing?

Over the past month, Tango Therapeutics, Inc.'s stock price has decreased by -2.99%.

How can I buy Tango Therapeutics, Inc. stock?

You can buy Tango Therapeutics, Inc. stock through any brokerage platform, such as e.g., Robinhood, Fidelity, E*TRADE, by searching for the ticker symbol TNGX

Who are the major shareholders of Tango Therapeutics, Inc. stock?

Major shareholders of Tango Therapeutics, Inc. include institutions such as Farallon Capital Management LP (9.70%), EcoR1 Capital, LLC (9.55%), TCG Crossover Management LLC (9.48%) ... , according to the latest filings.